Search

everythinglearnresearchcommunity

for

Search:↓

The research shows that hydrogen bonds greatly affect the crystal structure of a Finasteride derivative.

Finasteride is made through a series of chemical reactions starting from a specific intermediate compound.

A new method was developed to purify finasteride for better medical use.

A new method to make Finasteride is more cost-effective and yields 16%.

Methylated gene parts may cause finasteride-resistance in some enlarged prostate patients.

New compounds were made that effectively block enzymes related to prostate issues and hair loss.

Compound 15a was effective in inhibiting 5α-reductase.

GI198745 is more potent and longer-lasting than finasteride, potentially better for treating hair loss.

Researchers made two new compounds that could be used for medicine.

Methylation in specific gene region causes finasteride resistance in some BPH patients.

Finasteride effectively treats male hair loss, improving growth and density.

Finasteride effectively treats male pattern hair loss with a 1 mg daily dose.

The study found that two enzymes linked to hair loss are located in different parts of the scalp, supporting a common treatment's effectiveness.

New compounds were made that effectively block a specific enzyme related to androgen conditions.

Changing the C-ring structure in certain compounds can make them better at blocking a specific human enzyme.

The document concludes that the 5 alpha-reductase enzymes are important in steroid metabolism and related to various human diseases, with inhibitors used to treat conditions like male pattern baldness and prostate issues.

Certain 4-azasteroids are effective at blocking the enzyme that processes testosterone in human skin and could help treat acne, excessive hair growth, and male pattern baldness.

A new method was developed to make finasteride for treating hair loss.

LY191704 is a compound that effectively blocks a specific enzyme involved in hormone conversion and could help treat enlarged prostate and hair loss.

Selective non-steroidal inhibitors of 5α-reductase type 1 can help treat DHT-related disorders.

Accurate protein modeling can help develop new treatments for prostate cancer and other diseases.

FCE 28260 is a stronger and longer-lasting inhibitor of 5α-reductase than finasteride, which may make it a better treatment for certain medical conditions.

New steroidal compounds moderately block an enzyme related to testosterone conversion, less effectively than finasteride.

The compounds tested could potentially treat hair loss and alopecia.

A brominated phenoxy compound effectively inhibits a human enzyme and shows potential for clinical use.

Some cancer and immune system drugs can cause serious side effects, including heart, lung, nerve, and organ damage, which need careful monitoring and management.

Sebocytes play a key role in controlling androgen levels in human skin.

Three specific 4-azasteroid-2-oximes showed strong enzyme inhibition, but less than finasteride.

Finasteride's effect on hair loss and prostate enlargement depends on its binding to an enzyme, with maximum impact at 0.2 mg dose.

Finasteride modifies 5-alpha-reductases through a two-step process, affecting inhibitor potency and possibly causing side effects.